Article Details

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 ...

Retrieved on: 2021-07-15 20:03:45

Tags for this article:

Click the tags to see associated articles and topics

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 .... View article details on HISWAI: https://www.bakersfield.com/ap/news/corvus-pharmaceuticals-discontinues-phase-3-study-of-mupadolimab-anti-cd73-for-covid-19-due/article_45109d7a-8274-550b-9a9b-710b0047e360.html

Excerpt

Corvus' lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited ...

Article found on: www.bakersfield.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up